Revenue $1.74B, up 13.6% on a year earlier. Europe sales $439.60M, up 16.2%. Japan Sales $96.40M, up 1.2%. Diluted EPS $0.42 against $0.56.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.53B | +13.6% |
| Operating income | $513.20M | $477.60M | $411.20M | +24.8% |
| Net income | $241.40M | $380.70M | $333.20M | -27.6% |
| Diluted EPS | $0.42 | $0.66 | $0.56 | |
| Operating cash flow | $651.90M | $43.80M | $290.20M | +124.6% |
| Capital expenditures | -$66.90M | -$64.90M | -$49.30M | |
| Free cash flow | $585.00M | -$21.10M | $240.90M | +142.8% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Europe sales | $439.60M | $378.20M | +16.2% |
| Japan Sales | $96.40M | $95.30M | +1.2% |
| Rest of World Sales | $201.50M | $169.00M | +19.2% |
| U.S. sales | $1.00B | $889.70M | +12.8% |
| TAVR Sales | $1.26B | $1.13B | +11.3% |
| Surgical Structural Heart Sales | $284.10M | $266.80M | +6.5% |
| TAVR Sales Growth | 11.3% | 10% | |
| Underlying sales growth | 12.5% | 10.6% |
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| Q2 FY26 | Net Sales | $1.66B to $1.74B | $1.74B | in range |
| Q2 FY26 | Revenue | $1.66B to $1.74B | $1.74B | in range |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Edwards Lifesciences (EW) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/EW/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
